Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
On Sunday, Pfizer (NYSE:PFE) and AstraZeneca Plc (NASDAQ:AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France, j
Centogene Shares Are Trading Higher After the Company Reported a Year-over-year Increase in FY23 EPS Results.
Centogene Shares Are Trading Higher After the Company Reported a Year-over-year Increase in FY23 EPS Results.
4 Analysts Assess OncoCyte: What You Need To Know
Analysts' ratings for OncoCyte (NASDAQ:OCX) over the last quarter vary from bullish to bearish, as provided by 4 analysts.The table below summarizes their recent ratings, showcasing the evolving senti
Needham Reiterates Buy on OncoCyte, Maintains $4.25 Price Target
Needham analyst Mike Matson reiterates OncoCyte (NASDAQ:OCX) with a Buy and maintains $4.25 price target.
OncoCyte Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 54.55% Needham → $4.25 Reiterates Buy → Buy 04/24/2024 54.55% Needham $3.6 → $4.25 Maintains Bu
Quest Diagnostics Declares $0.75 Dividend